Why It Matters

Kidney Care Partners terminated its lobbying relationship with BGR Government Affairs LLC effective April 1, according to a termination disclosure filed in July. The health advocacy group had been working with the firm on federal policy matters affecting kidney disease treatment and care quality.

The termination marks the end of what had been a sustained engagement spanning multiple years. Kidney Care Partners had engaged BGR Government Affairs to provide guidance and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment.

By The Numbers

BGR Government Affairs charged Kidney Care Partners $80,000 per quarter in 2019, generating approximately $320,000 annually for the firm during that period. The contract represented a meaningful but not dominant part of BGR's health and life sciences portfolio. For context, the firm earned significantly more from other healthcare clients, collecting a total of $960,000 from Qualcomm Inc., $760,000 from Verizon Communications Inc., and $750,000 from the American Health Care Association across all filings.

Broader Context

Kidney Care Partners' lobbying efforts with BGR Government Affairs centered on health issues, specifically End Stage Renal Disease and Chronic Kidney Disease policy. In 2019, the organization was also engaged on funding for Kidney X, an innovation platform focused on kidney disease research and treatment.

The firm that previously represented Kidney Care Partners brought meaningful expertise to the account. Robb Walton, who served as Partner at BGR Government Affairs during the engagement, had prior experience on the Senate Health, Education, Labor and Pensions Committee. Matt Hoffmann, who served as Practice Co-Head and Principal, brought experience from multiple House committees including the Budget and Ways and Means committees, both relevant to healthcare funding debates.

The Bottom Line

The termination disclosure was filed on July 16, about three months after the relationship ended.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article